Safety and efficacy of the Russian COVID-19 vaccine: more information needed-Authors' reply (vol 396, pg e54, 2020)

被引：0

|

作者：

Logunov, D. Y.

Dolzhikova, I., V

Tukhvatullin, A., I

Shcheblyakov, D., V

机构：

来源：

LANCET | 2020年 / 396卷 / 10256期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：E56 / E56

页数：1

相关论文

共 8 条

[1] Safety and efficacy of the Russian COVID-19 vaccine: more information needed
Bucci, Enrico
Andreev, Konstantin
Bjorkman, Anders
Calogero, Raffaele Adolfo
Carafoli, Ernesto
Carninci, Piero
Castagnoli, Paola
Cossarizza, Andrea
Mussini, Cristina
Guerin, Philippe
Lipworth, Brian
Sbardella, Gianluca
Stocki, Teresa
Tuosto, Loretta
van Tulleken, Christoffer
Viola, Antonella
[J]. LANCET, 2020, 396 (10256): : E53 - E53
[2] Encouraging results from phase 1/2 COVID-19 vaccine trials (vol 396, pg 448, 2020)
Bar-Zeev, N.
Moss, W. J.
[J]. LANCET, 2020, 396 (10249): : 466 - 466
[3] Scientific consensus on the COVID-19 pandemic: we need to act now (vol 396, pg e71, 2020)
Jeger, R., V
Farah, A.
Ohlow, M-A
[J]. LANCET, 2020, 396 (10261): : 1490 - 1490
[4] Use of immunization information systems in ascertainment of COVID-19 vaccinations for claims-based vaccine safety and effectiveness studies (vol 6, e2313512, 2023)
Zhou, Cindy K.
[J]. JAMA NETWORK OPEN, 2023, 6 (06)
[5] RETRACTION: Efficacy and safety of acupuncture therapy for asymptomatic infection of COVID-19: A protocol for systematic review and meta-analysis (Retraction of Vol 99, art no E22697, 2020)
Huang, S.
Wang, S.
Li, G.
[J]. MEDICINE, 2021, 100 (11)
[6] Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia (vol 396, pg 887, 2020)
Logunov, D. Y.
Dolzhikova, I., V
Zubkova, O., V
[J]. LANCET, 2021, 397 (10269): : 98 - 98
[7] Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021)
Logunov, D. Y.
Dolzhikova, I., V
Shcheblyakov, D., V
[J]. LANCET, 2021, 397 (10275): : 670 - 670
[8] Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial (vol 22, pg P1703, 2022)
Nsio, J.
Ardiet, D-L
Coulborn, R. M.
[J]. LANCET INFECTIOUS DISEASES, 2023, 23 (01): : E1 - E1